A PYMNTS Company

US: 2012 pay-for-delay pharma deals cost consumers billions, says FTC report

 |  January 18, 2013

Acordingt to this report, the US Federal Trade Commission has released the results of a 2012 study and found that there was a sharp increase in pay-for-delay deals in the pharmaceutical industry, in which brand name and generic drug copanies made deals to keep generics off the shelves. Also according to the study, the deals cost citizens “billions” of dollars a year and added to the deferal deficit. According to the FTC repirt, drug companies made 40 of these deals in FY2012 (which ended September 30, 2012), and noted that the number was “significantly higher” than the 28 pay-for-delay deals made in FY2011. The FTC also found that nearly half of those 40 deals involved brand name companies promising not to market AG products that compete with generic company’s products.

Full Content: Intellectual Property Watch

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.